- Home
- NB vs PRLD Comparison
NB vs PRLD Comparison
Compare NB & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NB
- PRLD
- Stock Information
- Founded
- NB 1987
- PRLD 2016
- Country
- NB United States
- PRLD United States
- Employees
- NB N/A
- PRLD N/A
- Industry
- NB Metal Mining
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- NB Basic Materials
- PRLD Health Care
- Exchange
- NB Nasdaq
- PRLD Nasdaq
- Market Cap
- NB 150.3M
- PRLD 50.1M
- IPO Year
- NB N/A
- PRLD 2020
- Fundamental
- Price
- NB $2.43
- PRLD $0.83
- Analyst Decision
- NB Strong Buy
- PRLD Strong Buy
- Analyst Count
- NB 2
- PRLD 2
- Target Price
- NB $4.13
- PRLD $4.50
- AVG Volume (30 Days)
- NB 2.4M
- PRLD 111.3K
- Earning Date
- NB 05-20-2025
- PRLD 05-06-2025
- Dividend Yield
- NB N/A
- PRLD N/A
- EPS Growth
- NB N/A
- PRLD N/A
- EPS
- NB N/A
- PRLD N/A
- Revenue
- NB N/A
- PRLD $7,000,000.00
- Revenue This Year
- NB N/A
- PRLD N/A
- Revenue Next Year
- NB N/A
- PRLD N/A
- P/E Ratio
- NB N/A
- PRLD N/A
- Revenue Growth
- NB N/A
- PRLD N/A
- 52 Week Low
- NB $1.27
- PRLD $0.61
- 52 Week High
- NB $4.15
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- NB 50.14
- PRLD 49.32
- Support Level
- NB $2.38
- PRLD $0.73
- Resistance Level
- NB $2.57
- PRLD $1.00
- Average True Range (ATR)
- NB 0.21
- PRLD 0.09
- MACD
- NB -0.04
- PRLD -0.01
- Stochastic Oscillator
- NB 27.40
- PRLD 29.00
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.